Squarepoint’s Acurx Pharmaceuticals ACXP Stock Holding History

Squarepoint’s Portfolio ACXP Stock Details ACXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-627	Closed	-$10.2K	–	4490
2024 Q4	$10.2K	Buy	+627	New	+$18.9K	﹤0.01%	4956

Other funds holding ACXP

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PFS

Prospect Financial Services Melville, New York $164M AUM 19.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCWA

Vanguard Capital Wealth Advisors Denver, Colorado $148M AUM 91.21% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Squarepoint's ACXP Position: Q1 2025 in Review

Squarepoint sold out of Acurx Pharmaceuticals (ACXP) in Q1 2025, closing a stake of 627 shares — an estimated $10.2K sold.

Squarepoint first reported a position in ACXP in Q4 2024 and held it in 1 quarter. The position peaked at $10.2K in Q4 2024. 24 funds tracked by Wall St. Rank hold ACXP as of Q1 2025.

Squarepoint reported no remaining Acurx Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Squarepoint sold 627 Acurx Pharmaceuticals shares in Q1 2025, an estimated $10.2K.
Squarepoint first reported a position in Acurx Pharmaceuticals in Q4 2024 and held it in 1 quarter.
Squarepoint's Acurx Pharmaceuticals position peaked at $10.2K in Q4 2024.
24 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q1 2025.

Based on Squarepoint's 13F filing for Q1 2025, filed 15 May 2025.